We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Read MoreHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) announced that it has withdrawn its non-binding proposal to acquire Evotec SE (EVO - Free Report) for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value of €2.0 billion.
Halozyme decided to withdraw the acquisition bid following the unwillingness of Evotec’s management to discuss the potential buyout offer. EVO maintained its desire to remain an independent company.
Besides withdrawing the buyout offer, HALO also reaffirmed its 2024 revenue guidance that was provided last month.
Shares of Halozyme were up 7.2% on Nov. 22 following the announcement of the news. The stock has rallied 32.6% so far this year against the industry’s decline of 8.5%.
Image Source: Zacks Investment Research
More on HALO’s Recent Acquisition Offer
Earlier this month, Halozyme submitted its non-binding proposal to acquire Evotec for €11.00 per share in cash. The offer represented a premium of 109% to EVO's undisturbed share price on Oct. 15, 2024.
Shares of HALO tanked on the buyout offer.
Per Halozyme, the acquisition of EVO would have created a global services company with a distinctive set of technologies and an innovative deep pipeline. The buyout would have complemented Halozyme's ENHANZE drug delivery technology as well.
The acquisition would have diversified HALO’s business operation and also likely extended Halozyme’s revenues and EBITDA into the next decade and beyond.
Despite the lucrativeness of the buyout offer, Evotec’s management was not open to further discussions, which eventually led to HALO withdrawing the offer.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to 54 cents during the same time. Year to date, shares of SPRO have declined 21%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 38.1%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme Therapeutics, Inc. (HALO - Free Report) announced that it has withdrawn its non-binding proposal to acquire Evotec SE (EVO - Free Report) for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value of €2.0 billion.
Halozyme decided to withdraw the acquisition bid following the unwillingness of Evotec’s management to discuss the potential buyout offer. EVO maintained its desire to remain an independent company.
Besides withdrawing the buyout offer, HALO also reaffirmed its 2024 revenue guidance that was provided last month.
Shares of Halozyme were up 7.2% on Nov. 22 following the announcement of the news. The stock has rallied 32.6% so far this year against the industry’s decline of 8.5%.
Image Source: Zacks Investment Research
More on HALO’s Recent Acquisition Offer
Earlier this month, Halozyme submitted its non-binding proposal to acquire Evotec for €11.00 per share in cash. The offer represented a premium of 109% to EVO's undisturbed share price on Oct. 15, 2024.
Shares of HALO tanked on the buyout offer.
Per Halozyme, the acquisition of EVO would have created a global services company with a distinctive set of technologies and an innovative deep pipeline. The buyout would have complemented Halozyme's ENHANZE drug delivery technology as well.
The acquisition would have diversified HALO’s business operation and also likely extended Halozyme’s revenues and EBITDA into the next decade and beyond.
Despite the lucrativeness of the buyout offer, Evotec’s management was not open to further discussions, which eventually led to HALO withdrawing the offer.
HALO Maintains 2024 Guidance
Last month, along with its third-quarter earnings release, Halozyme raised its 2024 financial guidance.
Per the latest press release, the company maintained its 2024 financial guidance.
Halozyme expects total revenues in the range of $970 million to $1.02 billion in 2024, implying year-over-year growth of 13-22%.
Royalty revenues are anticipated in the range of $550-$565 million.
Adjusted EBITDA is expected to be between $595 million and $625 million in 2024, implying growth of 40% to 47% year over year.
The company expects adjusted earnings in the range of $4.00-$4.20 per share, indicating an improvement of 44-52% year over year.
HALO's Zacks Rank & Other Key Picks
Halozyme currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the biotech sector are Spero Therapeutics, Inc. (SPRO - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to 54 cents during the same time. Year to date, shares of SPRO have declined 21%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 38.1%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.